HBO Kennisbank

5 Resultaten

Sorteer op:

Zocht je misschien: wekken, wekkend, anthonijs, anthonie?

The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients

Zwierenga, Fenneke; Dijkhuizen, Christa (Biomolecules & Health); Korthuis, Patrick; Timens, Wim; Groen, Harry; Hiltermann, Jeroen; van den Berg, Anke; Drayer, Lyndsay; van der Wekken, Anthonie

Clinical outcomes in ROS1-fusion positive (ROS1+) non-small cell lung cancer (NSCLC) by fusion partner and resistance mechanisms are limited. This cohort study included 56 ROS1+ patients (FISH or NGS confirmed); fusion partners were identified in 27 cases, including CD74 (n = 10), EZR (n = 7), and SDC4 …

2025-08-29GezondheidArtikel

ROS1+ in vitro models

Dijkhuizen, Christa (Biomolecules & Health); Korthuis, Patrick; Aguado, Cristina; Garcia-Román, Silvia; Aguilar-Hernández, Andrés; Drayer, Lyndsay; Hiltermann, Jeroen; De Looff, Margot (Biomolecules & Health); Milder, Fin (Biomolecules & Health); van den Berg, Anke; van der Wekken, Anthonie

2025-06-17GezondheidConferentiebijdrage

Assessment of two new ROS1+ NSCLC patient-derived cell lines as in vitro models for TKI resistance studies

Dijkhuizen, Christa (Biomolecules & Health); Korthuis, Patrick; Aguado, Cristina; Garcia-Román, Silvia; Aguilar-Hernández, Andrés; Drayer, Lyndsay; De Looff, Margot (Biomolecules & Health); Milder, Fin (Biomolecules & Health); van der Wekken, Anthonie; van den Berg, Anke

2025-06-13GezondheidConferentiebijdrage

L2026M+G2032R variant confers resistance to ROS1 tyrosine kinase inhibitors in SCL34A2-ROS1 overexpressing Ba/F3 cells through a reduced ATP binding pocket volume

Dijkhuizen, Christa (Biomolecules & Health); Korthuis, Patrick; Vilachã, Juliana F.; Smelt, Maaike; van der Wekken, Anthonie; van den Berg, Anke; Drayer, Lyndsay

Background The ROS1 G2032R mutation is the most common on-target resistance mutation in crizotinib treated ROS1-positive lung cancer patients. The aim of our study was to investigate resistance mechanisms in SCL34A2-ROS1G2032R positive Ba/F3 cells against second line treatment with lorlatinib. Methods …

2023-10-21GezondheidConferentiebijdrage

SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume

Dijkhuizen, Christa (Biomolecules & Health); Korthuis, Patrick; Vilachã, Juliana F.; Smelt, Maaike; van der Wekken, Anthonie; van den Berg, Anke; Drayer, Lyndsay

2023GezondheidConferentiebijdrage

Vorige Volgende

The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients

ROS1+ in vitro models

Assessment of two new ROS1+ NSCLC patient-derived cell lines as in vitro models for TKI resistance studies

L2026M+G2032R variant confers resistance to ROS1 tyrosine kinase inhibitors in SCL34A2-ROS1 overexpressing Ba/F3 cells through a reduced ATP binding pocket volume

SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume

Over HBO Kennisbank